Drug
Sintilimab clinical trials
Also written IBI308.
- studies test it
- 353
- open now
- 182
- in phase 3
- 43
- first study started
- 2016
Keep track of what changes. Save the sintilimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- IBI308
- 69
Studies by the year they started
353 studies that test it; most in 2021 (58)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 12 |
| 2019 | 44 |
| 2020 | 40 |
| 2021 | 58 |
| 2022 | 46 |
| 2023 | 32 |
| 2024 | 42 |
| 2025 | 31 |
| 2026 | 44 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 51
- Phase 2
- 271
- Phase 3
- 43
- Phase 4
- 4
- No phase
- 15
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 45 · Other 308
Sun Yat-sen University (39) · Innovent Biologics (Suzhou) Co. Ltd. (35) · Fudan University (32) · Tianjin Medical University Cancer Institute and Hospital (20) · Zhejiang Cancer Hospital (10) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (10) · The First Affiliated Hospital with Nanjing Medical University (9) · Second Affiliated Hospital, School of Medicine, Zhejiang University (8)
Often tested with
Tested in the same studies.
Bevacizumab (27) · Lenvatinib (19) · Paclitaxel (16) · HMPL-013 (13) · Albumin-Bound Paclitaxel (13) · Anlotinib (12) · Tucidinostat (12) · Oxaliplatin (11)
Studies
Open first, then newest update. How each study uses sintilimab is read from its arms, and is right about nine times in ten.
Testing it · 353
- First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal MesotheliomaNot yet recruitingPhase 2Fudan UniversityNCT07893340Written as Sintilimab
- Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingPhase 2/3Yao HongweiNCT07879586Written as Ipilimumab & Sintilimab
- Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingPhase 2/3Yao HongweiNCT07879599Written as Ipilimumab & Sintilimab
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal CancerRecruitingPhase 2Fudan UniversityNCT06841159Written as Sintilimab
- A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction CancerNot yet recruitingPhase 2Fudan UniversityNCT07878221Written as Sintilimab
- Sintilimab Combined With Chemoradiotherapy as Neoadjuvant Therapy for Locally Advanced Gastroesophageal Junction CancerNot yet recruitingNot applicableAnhui Medical UniversityNCT07859410Written as Sintilimab
- A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)RecruitingPhase 2The Second Affiliated Hospital of Chongqing Medical UniversityNCT07852091Written as Sintilimab/Envafolimab
- Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 TrialRecruitingPhase 2Guangdong Provincial People's HospitalNCT07722754Written as Sintilimab
- Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell CarcinomaNot yet recruitingPhase 3caohaotianNCT07827872Written as Sintilimab
- Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerRecruitingPhase 2Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07061535Written as Sintilimab (approved)
- A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric CancerNot yet recruitingPhase 2Cancer Hospital Chinese Academy of Medical Science, Shenzhen CenterNCT07819019Written as Sintilimab
- Sequential PD-1 Antibody and Pegylated Interferon Therapy for Nucleos(t)Ide Analogue-suppressed Chronic Hepatitis BNot yet recruitingNot applicableBeijing 302 HospitalNCT07809165Written as Sintilimab
- Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After SurgeryRecruitingPhase 2The First Hospital of Jilin UniversityNCT07400302Written as Sintilimab
- Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07797816Written as Sintilimab
- A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular CarcinomaRecruitingPhase 1Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07557251Written as Sintilimab
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingPhase 4Zhai WenlongNCT07790419Written as Sintilimab+camrelizumab+tislelizumab
- IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric CancerRecruitingPhase 1/2Ruijin HospitalNCT07025889Written as Sintilimab
- GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell LymphomaNot yet recruitingPhase 2Fudan UniversityNCT07768943Written as Sintilimab
- Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2/3Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.NCT07643623Written as Sintilimab
- Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaNot yet recruitingPhase 1/2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07761286Written as Bevacizumab Injection + Sintilimab Injection
See all 353 studies that test sintilimab →
Given in every arm · 52 — sintilimab is usual care beside what is tested
- PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLMRecruitingPhase 2Fujian Cancer HospitalNCT06788171Written as Sintilimab
- Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon CancerRecruitingPhase 2Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT07840677Written as Sintilimab
- Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07831993Written as Sintilimab
- Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingPhase 2Shunda DuNCT07832006Written as Sintilimab
- First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingPhase 2Qilu Hospital of Shandong UniversityNCT06730373Written as Sintilimab
- HSK41959 With Standard Therapy in Solid Tumors With MTAP DeletionNot yet recruitingPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT07699757Written as Sintilimab
- Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled TrialNot yet recruitingPhase 3Guangdong Provincial People's HospitalNCT07686796Written as Sintilimab
- Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid TumorsNot yet recruitingPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT07612137Written as Sintilimab
- Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.RecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07394387Written as Sintilimab
- Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung CancerRecruitingPhase 1Sichuan UniversityNCT06431685Written as Sintilimab
- HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)RecruitingPhase 2Fudan UniversityNCT06860490Written as Sintilimab
- Denosumab Strategy for Liver Cancer With Bone MetastasesNot yet recruitingPhase 2Tongji HospitalNCT07537972Written as Sintilimab
- Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver CancerNot yet recruitingPhase 3Tongji HospitalNCT07537946Written as Sintilimab
- SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal CancerNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07535632Written as Sintilimab
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.RecruitingPhase 2/3Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.NCT07490262Written as Sintilimab
- Study of ABO2102 in KRAS-Mutated Solid TumorsRecruitingPhase 1Suzhou Abogen Biosciences Co., Ltd.NCT07455617Written as Sintilimab injection
- Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid TumoursRecruitingPhase 1ImmVirx Pty LtdNCT05427487Written as Sintilimab
- Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon AdenocarcinomaRecruitingPhase 2Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT07468630Written as Sintilimab
- XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic CancerRecruitingNot applicableWu WenmingNCT06353646Written as Sintilimab injection
- Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung CancerRecruitingPhase 2Sichuan UniversityNCT06121505Written as Sintilimab
Showing 20 of 52.
As the comparator · 10 — what is tested is compared with sintilimab
- QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07716449Written as Sintilimab
- A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)RecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06618664Written as Sintilimab
- ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced HepatocellularNot yet recruitingPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07813572Written as Sintilimab
- Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular CarcinomaRecruitingPhase 2Hebei Medical University Fourth HospitalNCT07179900Written as Sintilimab
- A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)RecruitingPhase 1/2AkesoNCT06530251Written as Sintilimab Injection
- Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLCNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06837948Written as Sintilimab
- Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06454435Written as Sintilimab + S-1 plus nab-paclitaxel
- A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingPhase 2/3Qilu Pharmaceutical Co., Ltd.NCT05976568Written as Sintilimab
- A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon CancerActive, not recruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT05890742Written as Sintilimab
- The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB PatientsActive, not recruitingNot applicableBeijing 302 HospitalNCT06357806Written as Sintilimab
Codes
What other systems call sintilimab · ClinicalTrials.gg INT001138
- MeSH (NLM) C000632826sintilimabOne source NLM
- UNII (FDA) 8FU7FQ8UPKSINTILIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q63313766sintilimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C132992SintilimabOne source FDA
- DrugBank DB15765One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000632826 | sintilimab | One source NLM |
| UNII (FDA) | 8FU7FQ8UPK | SINTILIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q63313766 | sintilimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C132992 | Sintilimab | One source FDA |
| DrugBank | DB15765 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.